BFG
MTNB icon

Bleakley Financial Group’s Matinas BioPharma MTNB Stock Holding History

Bleakley Financial Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,200
Closed -$9.5K – 1070
2024
Q2 		$9.5K Hold
1,200
– – ﹤0.01% 1013
2024
Q1 		$16.3K Hold
1,200
– – ﹤0.01% 990
2023
Q4 		$13K Hold
1,200
– – ﹤0.01% 945
2023
Q3 		$7.8K Hold
1,200
– – ﹤0.01% 880
2023
Q2 		$21.6K Hold
1,200
– – ﹤0.01% 916
2023
Q1 		$28.2K Hold
1,200
– – ﹤0.01% 888
2022
Q4 		$30K Buy
+1,200
New +$39.9K ﹤0.01% 851

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Bleakley Financial Group's MTNB Position: Q3 2024 in Review

Bleakley Financial Group sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 1,200 shares — an estimated $9.5K sold.

Bleakley Financial Group first reported a position in MTNB in Q4 2022 and held it in 7 quarters. The position peaked at $30K in Q4 2022. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Bleakley Financial Group reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Bleakley Financial Group sold 1,200 Matinas BioPharma shares in Q3 2024, an estimated $9.5K.
  • Bleakley Financial Group first reported a position in Matinas BioPharma in Q4 2022 and held it in 7 quarters.
  • Bleakley Financial Group's Matinas BioPharma position peaked at $30K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Bleakley Financial Group's 13F filing for Q3 2024, filed 16 Oct 2024.